The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study.
Abdenour Nabid
No relevant relationships to disclose
Nathalie Carrier
No relevant relationships to disclose
André-Guy Martin
No relevant relationships to disclose
Jean-Paul Bahary
No relevant relationships to disclose
Luis Souhami
No relevant relationships to disclose
Marie Duclos
No relevant relationships to disclose
François Vincent
No relevant relationships to disclose
Sylvie Vass
No relevant relationships to disclose
Boris Bahoric
No relevant relationships to disclose
Robert Archambault
No relevant relationships to disclose
Céline Lemaire
No relevant relationships to disclose